170 related articles for article (PubMed ID: 22705596)
21. [Cytokine profiles of multiple myeloma and Waldenström macroglobulinemia].
Sedlaříková L; Sadílková K; Kubiczková L; Hájek R; Sevčíková S
Klin Onkol; 2014; 27(1):18-23. PubMed ID: 24635433
[TBL] [Abstract][Full Text] [Related]
22. Distribution of HLA-G alternative mRNAs including soluble forms in normal lymphocytes and in lymphoid cell-derived leukemia.
Amiot L; Onno M; Drénou B; le Marchand B; Lamy T; Semana G; Fauchet R
Eur J Immunogenet; 1996 Aug; 23(4):311-20. PubMed ID: 8858287
[TBL] [Abstract][Full Text] [Related]
23. CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment.
Nair JR; Carlson LM; Koorella C; Rozanski CH; Byrne GE; Bergsagel PL; Shaughnessy JP; Boise LH; Chanan-Khan A; Lee KP
J Immunol; 2011 Aug; 187(3):1243-53. PubMed ID: 21715687
[TBL] [Abstract][Full Text] [Related]
24. Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.
Krejcik J; Frerichs KA; Nijhof IS; van Kessel B; van Velzen JF; Bloem AC; Broekmans MEC; Zweegman S; van Meerloo J; Musters RJP; Poddighe PJ; Groen RWJ; Chiu C; Plesner T; Lokhorst HM; Sasser AK; Mutis T; van de Donk NWCJ
Clin Cancer Res; 2017 Dec; 23(24):7498-7511. PubMed ID: 29025767
[No Abstract] [Full Text] [Related]
25. Gnawing Between Cells and Cells in the Immune System: Friend or Foe? A Review of Trogocytosis.
Zhao S; Zhang L; Xiang S; Hu Y; Wu Z; Shen J
Front Immunol; 2022; 13():791006. PubMed ID: 35185886
[TBL] [Abstract][Full Text] [Related]
26. TCL1 expression patterns in Waldenström macroglobulinemia.
Lemal R; Bard-Sorel S; Montrieul L; Bay JO; Ravinet A; Ledoux-Pilon A; Cagnard N; Bailly S; Morel P; Charlotte F; Leleu X; Poulain S; Déchelotte PJ; Hermine O; Leblond V; Tournilhac O; Guièze R
Mod Pathol; 2016 Jan; 29(1):83-8. PubMed ID: 26493619
[TBL] [Abstract][Full Text] [Related]
27. B and T cell markers in human proliferative blood diseases and primary immunodeficiencies, with special reference to membrane bound immunoglobulins.
Seligmann M; Preud'Homme JL; Brouet JC
Transplant Rev; 1973; 16():85-113. PubMed ID: 4204588
[No Abstract] [Full Text] [Related]
28. Cell surface markers in multiple myeloma.
Ruiz-Argüelles GJ; San Miguel JF
Mayo Clin Proc; 1994 Jul; 69(7):684-90. PubMed ID: 8015335
[TBL] [Abstract][Full Text] [Related]
29. B-cell malignancy and monoclonal gammopathy, and idiotype of cell surface and serum immunoglobulin.
Sugai S; Takiguchi T; Hirose Y; Konaka Y; Shimizu S; Konda S
Jpn J Clin Oncol; 1983 Sep; 13(3):533-42. PubMed ID: 6417376
[TBL] [Abstract][Full Text] [Related]
30. Chemokine-dependent B cell-T cell interactions in chronic lymphocytic leukemia and multiple myeloma - targets for therapeutic intervention?
Jöhrer K; Hofbauer SW; Zelle-Rieser C; Greil R; Hartmann TN
Expert Opin Biol Ther; 2012 Apr; 12(4):425-41. PubMed ID: 22332909
[TBL] [Abstract][Full Text] [Related]
31. Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals.
Gutiérrez NC; Ocio EM; de Las Rivas J; Maiso P; Delgado M; Fermiñán E; Arcos MJ; Sánchez ML; Hernández JM; San Miguel JF
Leukemia; 2007 Mar; 21(3):541-9. PubMed ID: 17252022
[TBL] [Abstract][Full Text] [Related]
32. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
Drent E; Groen RW; Noort WA; Themeli M; Lammerts van Bueren JJ; Parren PW; Kuball J; Sebestyen Z; Yuan H; de Bruijn J; van de Donk NW; Martens AC; Lokhorst HM; Mutis T
Haematologica; 2016 May; 101(5):616-25. PubMed ID: 26858358
[TBL] [Abstract][Full Text] [Related]
33. Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells.
Ray A; Das DS; Song Y; Richardson P; Munshi NC; Chauhan D; Anderson KC
Leukemia; 2015 Jun; 29(6):1441-4. PubMed ID: 25634684
[No Abstract] [Full Text] [Related]
34. Soluble HLA-G molecules are increased in lymphoproliferative disorders.
Sebti Y; Le Friec G; Pangault C; Gros F; Drénou B; Guilloux V; Bernard M; Lamy T; Fauchet R; Amiot L
Hum Immunol; 2003 Nov; 64(11):1093-101. PubMed ID: 14602240
[TBL] [Abstract][Full Text] [Related]
35. Preferential transfer of certain plasma membrane proteins onto T and B cells by trogocytosis.
Daubeuf S; Aucher A; Bordier C; Salles A; Serre L; Gaibelet G; Faye JC; Favre G; Joly E; Hudrisier D
PLoS One; 2010 Jan; 5(1):e8716. PubMed ID: 20090930
[TBL] [Abstract][Full Text] [Related]
36. B7+ T cells in myeloma: an acquired marker of prior chronic antigen presentation.
Brown R; Murray A; Pope B; Sze D; Gibson J; Ho PJ; Joshua D
Leuk Lymphoma; 2004 Feb; 45(2):363-71. PubMed ID: 15101725
[TBL] [Abstract][Full Text] [Related]
37. [On the cell surface markers of lymphocytes in lymphoproliferative disorders (author's transl)].
Tanaka E
Rinsho Ketsueki; 1976 Jun; 17(6):600-17. PubMed ID: 823349
[No Abstract] [Full Text] [Related]
38. Future directions in haematology: beyond multiple myeloma.
Prentice HG; Sacchi S; Russell N
Acta Haematol; 2005; 114 Suppl 1():27-32. PubMed ID: 16166770
[TBL] [Abstract][Full Text] [Related]
39. Trogocytosis-based generation of suppressive NK cells.
Caumartin J; Favier B; Daouya M; Guillard C; Moreau P; Carosella ED; LeMaoult J
EMBO J; 2007 Mar; 26(5):1423-33. PubMed ID: 17318190
[TBL] [Abstract][Full Text] [Related]
40. HLA-G in human early pregnancy: control of uterine immune cell activation and likely vascular remodeling.
Le Bouteiller P
Biomed J; 2015; 38(1):32-8. PubMed ID: 25163504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
